2022
Concurrent prescribing of opioids with other sedating medications after cancer diagnosis: a population-level analysis
Check D, Baggett C, Kim K, Merlin J, Oeffinger K, Winn A, Roberts M, Robinson T, Dinan M. Concurrent prescribing of opioids with other sedating medications after cancer diagnosis: a population-level analysis. Supportive Care In Cancer 2022, 30: 9781-9791. PMID: 36396793, DOI: 10.1007/s00520-022-07439-y.Peer-Reviewed Original ResearchConceptsConcurrent prescribingSedating medicationsPatient characteristicsMedication-related eventsRetrospective cohort studyNon-metastatic cancerPopulation-based assessmentCancer registry dataMental health conditionsSubstance use disordersPrivate insurance claimsConcurrent prescriptionsCohort studyHispanic patientsSymptom managementRelative riskRegistry dataGabapentinoidsOpioidsPrescribingUse disordersPatientsPoisson regressionPrior useMedications
2021
Patient- and provider-level predictors of mortality among patients with metastatic renal cell carcinoma receiving oral anticancer agents.
Spees L, Dinan M, Jackson B, Baggett C, Wilson L, Greiner M, Kaye D, Zhang T, George D, Scales C, Pritchard J, Leapman M, Gross C, Wheeler S. Patient- and provider-level predictors of mortality among patients with metastatic renal cell carcinoma receiving oral anticancer agents. Journal Of Clinical Oncology 2021, 39: 116-116. DOI: 10.1200/jco.2020.39.28_suppl.116.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaOral anti-cancer agentsPatients' clinical characteristicsProvider-level factorsCause mortalityRenal cell carcinomaClinical characteristicsHazard ratioMetastatic diagnosisCell carcinomaState cancer registry dataCox proportional hazards modelProvider-level predictorsLower overall survivalOral anticancer agentsCancer registry dataReal-world populationProportional hazards modelSkilled nursing facilitiesProvider Enumeration SystemAnti-cancer agentsIndex dateOverall survivalPatient demographicsBlack patientsProvider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma.
Spees L, Wheeler S, Jackson B, Baggett C, Wilson L, Greiner M, Kaye D, Zhang T, George D, Scales C, Pritchard J, Leapman M, Gross C, Dinan M. Provider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma. Journal Of Clinical Oncology 2021, 39: 87-87. DOI: 10.1200/jco.2020.39.28_suppl.87.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaPatient-level factorsProvider-level factorsRenal cell carcinomaIndex dateRace/ethnicityInitial diagnosisCell carcinomaRisk ratioState cancer registry dataNumber of comorbiditiesMore comorbid conditionsPatient-level predictorsCancer registry dataProportion of daysProvider-level variablesPrescription drug filesMedian PDCMRCC diagnosisMRCC patientsPatient characteristicsPharmacy claimsComorbid conditionsMetastatic diagnosisMedical oncologyProvider‐ and patient‐level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma
Spees LP, Wheeler SB, Jackson BE, Baggett CD, Wilson LE, Greiner MA, Kaye DR, Zhang T, George D, Scales CD, Pritchard JE, Leapman M, Gross CP, Dinan MA. Provider‐ and patient‐level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma. Cancer Medicine 2021, 10: 6653-6665. PMID: 34480518, PMCID: PMC8495289, DOI: 10.1002/cam4.4201.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaPatient-level factorsRenal cell carcinomaCell carcinomaRisk ratioState cancer registry dataPatient-level predictorsPatient-level characteristicsCancer registry dataProvider Enumeration SystemMRCC diagnosisMedical oncologyInsurance typeMedicare patientsRegistry dataFemale providersPatientsMedian proportionPoisson regressionCare issuesPrivate insuranceMale providersAdherenceCarcinomaAnticancer agentsPredictors of Chronic Opioid Use: A Population-Level Analysis of North Carolina Cancer Survivors Using Multi-Payer Claims
Check DK, Baggett C, Kim K, Roberts AW, Roberts MC, Robinson T, Oeffinger KC, Dinan MA. Predictors of Chronic Opioid Use: A Population-Level Analysis of North Carolina Cancer Survivors Using Multi-Payer Claims. Journal Of The National Cancer Institute 2021, 113: 1581-1589. PMID: 33881543, PMCID: PMC8562975, DOI: 10.1093/jnci/djab082.Peer-Reviewed Original ResearchConceptsChronic opioid useChronic opioid therapyOpioid useCancer survivorsOpioid therapyBaseline depressionLong-term pain managementSubstance useRetrospective cohort studyPopulation-based studyCancer registry dataLow-income survivorsCohort studyPatient characteristicsPain managementActive treatmentNonmetastatic cancerChronic useInsurance statusRelative riskRegistry dataOpioidsPoisson regressionYounger ageAge groups